Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
出版年份 2022 全文链接
标题
Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
作者
关键词
-
出版物
Cell Death Discovery
Volume 8, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-11-28
DOI
10.1038/s41420-022-01256-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation
- (2022) Shi-Suo Du et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
- (2022) Jonathan D Schoenfeld et al. LANCET ONCOLOGY
- cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy
- (2022) Zi-Jie Long et al. MOLECULAR THERAPY
- Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer
- (2022) Meng Yuan et al. Oxidative Medicine and Cellular Longevity
- Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer
- (2022) Xiaohua Jie et al. Journal for ImmunoTherapy of Cancer
- Type I interferon-mediated tumor immunity and its role in immunotherapy
- (2022) Renren Yu et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab
- (2022) Alex K. Bryant et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway
- (2022) Jessica Marinello et al. BRITISH JOURNAL OF CANCER
- Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
- (2021) Jun-Yan Li et al. Molecular Cancer
- Fractionated radiation severely reduces the number of CD8+ T cells and mature antigen presenting cells within lung tumors
- (2021) E. Reijmen et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
- (2021) Sandra Demaria et al. Journal for ImmunoTherapy of Cancer
- Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma
- (2021) Yan Huang et al. RADIOTHERAPY AND ONCOLOGY
- Low Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
- (2021) Fernanda G Herrera et al. Cancer Discovery
- Monitoring Early Glycolytic Flux Alterations Following Radiotherapy in Cancer and Immune Cells: Hyperpolarized Carbon-13 Magnetic Resonance Imaging Study
- (2021) Ying-Chieh Lai et al. Metabolites
- Radiotherapy and immunotherapy for cancer: From "systemic" to "multi-site"
- (2020) Ainhoa Arina et al. CLINICAL CANCER RESEARCH
- Tissue-resident memory T cells in breast cancer control and immunotherapy responses
- (2020) Ann Byrne et al. Nature Reviews Clinical Oncology
- Effect of low-dose radiotherapy on abscopal responses to hypofractionated radiotherapy and anti-PD1 in mice and NSCLC patients
- (2020) Limei Yin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
- (2020) Shaochuan Liu et al. Cell Death & Disease
- ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
- (2020) Hailong Sheng et al. Journal for ImmunoTherapy of Cancer
- Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling
- (2020) Alice Lepelley et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Bip inhibition in glioma stem cells promotes radiation-induced immunogenic cell death
- (2020) Wei Yang et al. Cell Death & Disease
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
- (2020) Willemijn S M E Theelen et al. Lancet Respiratory Medicine
- Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer
- (2019) Sha Zhao et al. Cancer Immunology Research
- Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer
- (2019) Xuefei Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- Targeting DNA repair in cancer: current state and novel approaches
- (2019) Apostolos Klinakis et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma
- (2019) Junbin Liao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
- (2018) Ariel E. Marciscano et al. CLINICAL CANCER RESEARCH
- Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
- (2018) Binyan Lin et al. GENE
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
- (2018) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers
- (2018) Le Ying et al. OncoImmunology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage
- (2018) Gillian Dunphy et al. MOLECULAR CELL
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Mitotic progression following DNA damage enables pattern recognition within micronuclei
- (2017) Shane M. Harding et al. NATURE
- Cytoplasmic chromatin triggers inflammation in senescence and cancer
- (2017) Zhixun Dou et al. NATURE
- cGAS is essential for the antitumor effect of immune checkpoint blockade
- (2017) Hua Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin
- (2017) Han Zhao et al. CELLULAR ONCOLOGY
- Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
- (2016) Yongkun Sun et al. Journal of Hematology & Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Activation of STING requires palmitoylation at the Golgi
- (2016) Kojiro Mukai et al. Nature Communications
- Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells
- (2015) Hui Gao et al. CANCER LETTERS
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Role of Local Radiation Therapy in Cancer Immunotherapy
- (2015) Sandra Demaria et al. JAMA Oncology
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Selective Targeting of the G2/M Cell Cycle Checkpoint to Improve the Therapeutic Index of Radiotherapy
- (2014) M.T. Dillon et al. CLINICAL ONCOLOGY
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Inflammation-driven carcinogenesis is mediated through STING
- (2014) Jeonghyun Ahn et al. Nature Communications
- Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
- (2013) Felix Klug et al. CANCER CELL
- Toxicity of Concurrent Radiochemotherapy for Locally Advanced Non–Small-Cell Lung Cancer: A Systematic Review of the Literature
- (2013) Caro C. Koning et al. Clinical Lung Cancer
- Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
- (2013) Melissa G. Lechner et al. JOURNAL OF IMMUNOTHERAPY
- Double-strand break repair: 53BP1 comes into focus
- (2013) Stephanie Panier et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells
- (2009) Kenji Chamoto et al. CANCER SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now